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Abstract
Prostate cancer is the second most frequently diagnosed cancer of men (913 000 new cases, 13.8% of the total)
and the fifth most common cancer overall. Prostate cancer is the sixth leading cause of death from cancer in men
(6.1% of the total).
The incidence of prostate cancer in Nigerian men is believed to be on the increase and it had become the
number one cancer in 1999, constituting 11% of all male cancers in the population served by the Ibadan cancer
Registry. Studies from Ibadan and from other sites in Nigeria (Benin, Calabar, Kano, Lagos, Maiduguri, and Zaria)
have shown an increasing incidence of prostate cancer accounting for anything between 6 and 12 % of total
cancers in these centres and up to about 18% of prostatic neoplasms in some. Most patients present in late stage
disease, and the mortality is high.
It is uncertain whether there is a biophysical component to the increased incidence of prostate cancer in Nigerian
and other West African men although a few studies point in this direction.
It appears there is inadequate information regarding the incidence and mortality of prostate cancer, and that
health care professionals do not routinely provide information regarding the importance of screening for prostate
cancer before age 50 for high-risk populations.
The Revised National health Policy for Nigeria (Sept 2004) has as its long term goal ‘to provide the entire
population with adequate access, not only to primary health care but also to secondary and tertiary services
through a well functioning referral system’ and also “Ensuring equitable distribution of human resources for
healthcare delivery between urban and rural areas, including difficult terrain, such as mountainous, riverine and
inaccessible areas of the country.”
At the moment however, Public expenditure on health is less than $8 per capita, compared to the $34
recommended internationally. Private expenditures are estimated to be over 70% of total health expenditure, most
of this from out-of-pocket. Yet there is endemic poverty. The National Health Insurance scheme (NHIS) is presently
severely limited in its allowances and certainly so for cancer care.
Conclusions: The following recommendations are therefore made:
* Establishment of community outreaches for education and screening.
* Improved completeness of records to understand the real burden of disease and funding studies to explore
biophysical components that may be important in racial differences for this disease.
* Increased access by increasing numbers of specialists required for clinical assessment and management.
* Increase laboratory diagnostic support
* Improved availability of drugs for the treatment of prostate cancer cases.
Correspondence: fogunbiyi@comui.edu.ng
Department of pathology, University College Hospital/ College of medicine,
University of Ibadan, P.M.B. 5116, Ibadan, Oyo state, Nigeria
Ogunbiyi Infectious Agents and Cancer 2011, 6(Suppl 2):S5
http://www.infectagentscancer.com/content/6/S2/S5
© 2011 Ogunbiyi; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Prostate cancer is the second most frequently diagnosed
cancer of men (913 000 new cases, 13.8% of the total)
and the fifth most common cancer overall. With an esti-
mated 258 000 deaths in 2008, prostate cancer is the
sixth leading cause of death from cancer in men (6.1% of
the total). [1]
Incidence rates for prostate cancer vary by more
than 25-fold worldwide, with the highest rates seen in
Australia/New Zealand (104.2 per 100,000), Western
and Northern Europe, and Northern America. This is
probably because prostate specific antigen (PSA) test-
ing and subsequent biopsy has become widespread in
those regions. PSA screening has been recommended
for Caucasian, Asian, and Hispanic men at age 50 but
because one of the most important risk factors
for prostate cancer in the United States is African-
American descent, African-Americans are screened
from age 45. [2] There is less variation in mortality
rates worldwide (10-fold) than is observed for inci-
dence, because PSA testing has a much greater effect
on incidence than on mortality, and the number of
deaths from prostate cancer is almost the same in
developed and developing regions. [3] Mortality rates
are generally high in predominantly black populations
(Caribbean, 26.3 per 100,000 and sub-Saharan Africa,
ASRs 18-19 per 100,000), very low in Asia (ASR 2.5
per 100,000 in Eastern Asia for example) and inter-
mediate in Europe and Oceania.
Methods
A review of available reports on the incidence and mor-
tality of prostate cancer in Nigeria and West Africa,
including modalities available for diagnosis and
treatment.
Results
The incidence of prostate cancer in Nigerian men is
believed to be on the increase and it had become the
number one cancer in 1999, constituting 11% of all
male cancers, moving ahead of hepatocellular carcinoma
in incidence and mortality in the population served by
the Ibadan cancer Registry. [4]
Studies from Ibadan and from other sites in Nigeria
(Benin, Calabar, Kano, Lagos, Maiduguri, and Zaria)
have shown an increasing incidence of prostate cancer.
In one study, there was a 7.7-fold increase over a 10-
year period. Prostate cancer accounts for anything
between 6 and 12 % of total cancers in these centres
and up to about 18% of prostatic neoplasms in some.
Interestingly the average age from the different subpo-
pulations is in the 7
th decade and the ages range from
40+ to 90+. [5-10]
In all sites, patients present in late stages of disease with
an average duration of symptoms of 6-8 months, and tend
to die within 2 – 3 years, except for a few exceptions (one
patient was alive 46 months after presenting with what
was diagnosed as orbital metastasis of prostate cancer).
[11] There however seems to be a gradual shift from pre-
dominantly high grade tumours towards intermediate
g r a d et u m o u r si nt h ed a t af r o mI b a d a n( F i g u r e1 ) .I n c i -
dence data is however still inadequate.
Because of the usually late presentation, most reported
patients have been treated with orchidectomy or other
forms of hormonal intervention by drugs. It is known
that they eventually become resistant to these hormonal
manipulations. For metastatic disease, radiation therapy
has been used. [12] Again, reports of survival studies are
nearly unavailable.
Discussion
This disparity in outcome, when compared to African
Americans, raises the following issues about prostate
cancer in Nigeria and West Africa in general:
*Is there adequate information regarding the incidence
and mortality of prostate cancer? The latest cancer inci-
dence publication of the International Agency for
research on Cancer (IARC) shows no representation of
cancer data from West Africa. There are not many can-
cer registries that submit reliable data that meet the
inclusion criteria for that publication and figures from
G L O B O C A Na r em a i n l ye x t r a p o l a t i v e .T h e r ea r eo n l y
two population based cancer registries in Nigeria and
data from these have not been accepted recently by the
CIV (Cancer Incidence in Five Continents) group of the
IARC. [13]
*Do health care professionals routinely provide infor-
mation regarding the importance of screening for pros-
tate cancer before age 50 for high-risk populations? As
far as we know, there is no established prostate cancer
screening programme in Nigeria and many of the West
African Countries. There is a recent attempt as establish-
ing a programme in Senegal. The challenges are that
there are not enough trained Urologists in any of these
countries, most of these are located in practices within
the big urban centres, and there is inadequate support
for follow up treatment for those that might be detected.
*Is there a biophysical component to the increased inci-
dence of prostate cancer in Nigerian and other West
African men? There is some literature in support of this at
the moment but the extent of this needs further enquiry.
Ukoli et al found central adiposity to be a positive predic-
tor of elevated PSA amongst a subset of Nigerians in one
study, after adjusting for age and enlarged prostate. [14] In
addition, molecular mechanisms have been shown
involved in racial disparities in prostate cancer. [15]
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less fat and increasing fruit and vegetable consumption,
reduce the incidence of prostate cancer in these
populations?
*Do current screening techniques of prostate specific
antigen (PSA) testing and digital rectal examination
(DRE) adequately detect early prostate cancer?
There is a whole controversy as to the exact useful-
ness of screening techniques but there is agreement that
a combination of PSA measurement, digital rectal exam-
ination (DRE), and prostatic ultrasound scanning will
significantly improve detection rates for early cancer.
With the pyramidal structure of our healthcare system
(Figure 2)in which only the smallest proportion of the
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Figure 1 Trend in incidence from 2000- 2009(Ibadan cases only)
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Figure 2 The distribution of healthcare facilities
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the larger proportion live in the villages, there is
obviously a disproportionate access to specialist care
and laboratory support for the much needed screening
programmes.
There is a Revised National health Policy for Nigeria
(Sept 2004) that is derived from the policy promulgated
in 1988 which seems to acknowledge these challenges
because ‘Its long term goal is to provide the entire popu-
lation with adequate access, not only to primary health
care but also to secondary and tertiary services through a
well functioning referral system.’ On p.31 of the National
Health policy document, under ‘national health human
resource development 2.’ It states “Ensuring equitable
distribution of human resources for healthcare delivery
between urban and rural areas, including difficult terrain,
such as mountainous, riverine, and inaccessible areas of
the country.” [16]
At the moment however, Public expenditure on health
is less than $8 per capita, compared to the $34 recom-
mended internationally. Private expenditures are esti-
mated to be over 70% of total health expenditure, most
of this from out-of-pocket. Yet there is endemic poverty.
There is a National Health Insurance scheme (NHIS)
presently, which is severely limited in its allowances and
certainly so for cancer care.
Conclusions
The following recommendations seem appropriate at
this time and are therefore made:
* Establishment of community outreaches for educa-
tion and screening.
* Improved completeness of records to understand the
real burden of disease
* Increased access to care by increasing the numbers
of specialists required for clinical assessment and
management.
* Increase laboratory diagnostic support
* Improved availability of drugs for the treatment of
cancers.
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